This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Zecuity

Teva Pharmaceutical Industries Ltd.

Drug Names(s): NP101, transdermal sumatriptan, Zelrix

Description: NP101 is a single-use patch that combines NuPathe's proprietary SmartRelief iontophoretic transdermal technology with sumatriptan.

Deal Structure: Endo and NuPathe
In December 2013, Endo and NuPathe entered into a definitive agreement under which Endo will acquire NuPathe for $2.85 per share in cash, or approximately $105 million. In addition to the upfront cash payment, NuPathe shareholders will receive rights to receive additional cash payments of up to $3.15 per share if specified net sales of NuPathes migraine treatment ZECUITY are achieved over time.

In January 2014, NuPathe terminated the definitive agreement with Endo. Endo received a $5 million termination fee from NuPathe.

NuPathe and Teva
In January 2014, NuPathe entered into an agreement and plan of merger with Teva under which Teva will acquire NuPathe for $3.65 per share in cash. In addition to the upfront cash payment, NuPathe stockholders will receive rights to receive additional cash payments of up to $3.15 per share if specified net sales of ZECUITY are achieved over time. Under the terms of the agreement, an affiliate of...See full deal structure in Biomedtracker


Zecuity News

Pink Sheet Zecuity Reviewers


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug